

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of

Harrington J. *et al.*

Art Unit: 1632

Application No.: 09/484,331

Examiner: R. Shukla

Filed: January 18, 2000

Atty. Docket: 0221-0003L

For: Compositions and Methods
For Non-Targeted Activation
of Endogenous Genes

DECLARATION UNDER C.F.R. § 1.132

Assistant Commissioner of
Patents and Trademark
Washington, D.C. 20231

Sir:

The undersigned, Youssef L. Bennani, declares and states:

1. I am Director of Medicinal Chemistry at Athersys, Inc., the subject of the attached Curriculum Vitae and author of the publications shown on the list attached thereto. I was trained as an organic chemist from 1980-1991 (PhD) and have practiced in the field of medicinal chemistry and drug discovery for the past 12 years. I have been part of and led several drug discovery programs in various therapeutic areas at some of the top biopharmaceutical and pharmaceutical companies in the world, including Ligand Pharmaceuticals and Abbott Laboratories. To date, I have been associated with and responsible for discovering 5 or more drugs, one of which is a marketed drug, while others are in various pre-clinical and clinical stages of development. On the basis of

information and facts contained in the above documents and on the basis of my professional history discussed above, I submit that I am an expert in the field of drug discovery and am qualified to speak on the skill and knowledge of the person of ordinary skill in this field.

2. I have read and understand the subject matter of the above-captioned application. I have read and understand the Office Action dated October 25, 2001, rejecting claims 62-68. It is my opinion, based on the scientific evidence and reasons set forth below and in view of my professional experience, that the methods that are the subject of the rejected claims were fully supported by the specification of the above-captioned application and could have been made and used by the person of ordinary skill in the art, as claimed, as of the filing date of September 26, 1997 (Applicants' earliest effective priority date) by routine and ordinary experimentation, using the Applicants' specification as a guide.

Written Description

3. On the issue of written description, it is my understanding that the Examiner has rejected the claims because he believes that the structure of the compound in the claims is critical to practicing the claimed methods and because the specification does not disclose the structures for compounds to be tested, i.e., that there is no "written description" for the compounds.

As I discussed with the Examiner in the interview held on April 17, 2002, the structure of compounds to be tested for activity in the drug discovery process (such as the process claimed) is not critical. Claims 62-68 contain information that can be viewed as an integral part of the drug discovery process. Drug discovery can begin with a cellular system, such as the one described in the above-mentioned claims (62-68), against which random compound libraries are screened for biological activity. It is typical and routine for such screening efforts to encompass large numbers of compounds (in the ten-hundred thousands or millions) in order to maximize hit rates. It is extremely difficult and highly discouraged to pre-select for compounds in such cell-based assays. Therefore, at this stage of the drug discovery process*, compound structure is not a consideration.

*A brief description of the drug discovery process:

- A) A gene is linked to a disease state by biochemical, molecular or physiological methods.
- B) An in-vitro biochemical or cellular assay (functional or phenotypic) in which such a gene is activated is established.
- C) The protein or the cellular system/assay is treated with a compound library containing hundreds to millions of chemical entities (small molecules, peptides, natural products, natural proteins etc.) of wide structural diversity.

- D) The ability of any of these chemical entities to perturb (activate or inhibit the protein of interest) in such an assay is determined by physical-chemical methods.
- E) The identity of such chemical entities or hits is determined.
- F) Such hits are further evaluated for their ability to provide benefit in an in-vivo model of disease and further improved upon based on the resulting data.
- G) Additional chemical modification results/should result in chemical entities with acceptable drug parameters (target selectivity, oral bio-availability, efficacy and safety).
- H) Such a chemical entity is advanced into human clinical trials.

Enablement

4. On page 7 of the Office Action, the Examiner states that the person of ordinary skill in the art could not determine whether a compound that was isolated by the claimed screening method would have any of the properties of a drug. It is not clear to me why the Examiner believes this. I do not agree with this because such chemical entity, once isolated, constitutes a conventional focal point of the drug discovery process. Such a compound typically contains physical-chemical drug features that may or may not need to be further ameliorated in order to meet all the drug criteria (target selectivity, oral bio-availability, efficacy, good therapeutic index, manufacturing feasibility etc.). It is typical and routine to perform these determinations. Drawing from personal experience I have been involved in several projects that started with a high throughput-screening

program. This allowed the identification of hits, some of which had good drug-like properties that were further modified to become chemical entities with profiles acceptable for clinical drug development. A large majority of drugs, in clinical practice today, have been discovered following a path similar to the drug discovery path described above. This is common practice in our industry.


5. In the paragraph spanning pages 7 and 8 of the Office Action the Examiner states that the person of ordinary skill in the art would not know how to use the claimed method because the specification only discloses that the RAGE-activated cells can be used for drug discovery and that “drug discovery” alone would not convey the specific steps in the claims, particularly steps d and e of claim 62 and step d of claim 63. From this position the Examiner then concludes that the person of ordinary skill in the art would not be able to practice the claimed methods. I do not agree.

In my experience and opinion, the person of ordinary skill in the art (i.e., drug discovery) would immediately recognize the claimed method in the term “drug discovery” and would know how to use the RAGE-activated cells for drug discovery, including the well-known and fundamental steps used in such research field. As mentioned above, a cell-based assay is an integral part of the drug discovery process known to the person of ordinary skill in the art. This assay would be known to necessarily include the steps of treating the cell with a test compound (step C above) and

determining the effect of the test compound on the target (step D above). Therefore, it is my opinion that the artisan would know how to use the RAGE-activated cells for all the steps in the claimed process.

6. In summary, I base my opinions and conclusions on the following:

- a. RAGE-activated cells expressing a protein or other phenotype of interest can constitute the first step in the drug discovery process.
- b. Cell-based assays are routinely used to randomly screen for compounds, off the shelf, from compound collection libraries, or combinatorial libraries with biochemical or biological activities.
- c. Once such compounds are discovered, further chemical modification helps address the various criteria that make up a drug such as: good solubility, good absorption, good tissue distribution, good bio-availability, selectivity and efficacy in the disease of interest as well as good and acceptable safety index.
- d. The term "drug discovery" conveys the steps of treating a cell with a compound and determining the effect of the compound



Youssef L. Bennani, Ph. D.

4/24/02

Date



Youssef L. Bennani Ph.D.

Citizenship: US
Address: 21200 Claythorne Rd. Shaker Heights, OH 44122
Phone #'s: 216-464-8844 (Home); 216-426-3591 (Bus. direct)
email: Bennaniy@AOL.com or ybennani@athersys.com

Objective: An executive leadership position in the management of a drug discovery team.

Professional Experience

2001-Present **Director of Medicinal Chemistry**
Athersys Inc., Cleveland, Ohio

1998-2001 **Senior Group Leader**
Neurological Diseases Research; Global Pharmaceutical R&D-Abbott Laboratories.
• Directed the efforts of 2 chemistry groups (25 Ph.D. & MS/BS level chemists)
• Co-inventor: **ABT-239** (ADHD, psychiatric disorders & obesity) in human Phase I
• Inventor: **ABT-086** (epilepsy/bipolar/migraine disorders) in late pre-clinical phase
• Filed 17 patent applications (large array of chemical platforms/indications)
• Functions included heading chemistry; scientific and managerial cross-functional interactions with process chemistry, pharmacology, biology, ADMET groups
• Scientific-Project presentations to senior scientific and management teams

1997-1998 Infectious Diseases Research; Global Pharmaceutical R&D-Abbott Laboratories.
• Directed the efforts of 3 Group Leaders with 24 Ph.D. & MS/BS level chemists
• Research on novel anti-fungal cyclic lipopeptides: one out-license candidate
• Research on yeast-specific translation factors-Ribogene-collaboration
• Research on Non-immune-suppressive antifungal rapamycin analogues
• Research on anti-GERD agents: **ABT269**, back-up phase II-clinical agent

1996-1997 **Group Leader**
Metabolic Diseases Research, Global Pharmaceutical R&D-Abbott Laboratories.
• Directed the efforts of 2 Ph.D. and 2 MS level chemists working on growth factors modulation.

1993-1996 **Research Scientist**
Medicinal Chemistry, Ligand Pharmaceuticals Inc., USA.
• Directly involvement in pre-clinical studies of FDA approved & marketed **LGD1057: Panretin® & LGD1550 (co-inventor)** (Phase I-IIa) for the treatment of APL & other cancers.
• Co-inventor: tricyclic retinoids and novel aza-retinoids as selective RXR modulators.

1991-1993 **Postdoctoral Research Fellow**
The Scripps Research Institute, La Jolla, CA, USA; K.B. Sharpless (2001-Nobel Laureate)
• Worked to the development, applications and mechanism of the AD-reaction.

Education

1997-2000	<i>Masters in Business Administration (MBA)-w/distinction</i> Lake Forest Graduate School of Management, IL, USA.
1986-1991	<i>Philosophy Doctorate in Chemistry (Ph.D.)</i> University of Montreal, Canada, S. Hanessian Laboratories.
1981-1986	<i>Bachelor's & Masters in Chemistry (BS/MS)</i> University of Montreal, Canada, S. Hanessian Laboratories.

References

- Dr. Andre G. Pernet, CEO-Genset SA (Paris) 33-1-55-04-5900; Ex-VP-R&D, Abbott Labs.
- Dr. Mike Williams, Vice President-Drug discovery, Molecumetics; Tel: 425-990-7437
- Dr. Dave W. Robertson; VP-Research-Neurology, Pfizer; Tel: 616-833-1634
- Professor K. Barry Sharpless; The Scripps Research Institute; Tel: 619-784-7505
- Professor Stephen Hanessian; University of Montreal; Tel: 514-343-6738

Addendum
(Youssef L. Bennani Ph.D.)

Publications

- S. Hanessian, D. Desilets and Y. L. Bennani "A Novel Ring Closure Strategy for the Carbapenems: The Total Synthesis of (+)-Thienamycin" *Journal of Organic Chemistry*, **1990**, *55*, 3098.
- F. Bélanger-Gariépy, Y. L. Bennani, S. Hanessian and F. Brisse "Structure of a Chiral Chloropropyl Phosphonamide" *Acta Cryst.*, **1989**, *C45*, 289.
- Y. L. Bennani, F. Bélanger-Gariépy and S. Hanessian "Structure of a Chiral Azidopropyl Phosphonamide" *Acta Cryst.*, **1990**, *C46*, 653.
- S. Hanessian, Y. L. Bennani and D. Delorme "The Asymmetric Synthesis of α -Chloroalkyl, α -Methylalkyl Phosphonic Acids of High Enantiomeric Purity" *Tetrahedron Letters*, **1990**, *31*, 6461.
- S. Hanessian and Y. L. Bennani "A Versatile Asymmetric Synthesis α -Amino Alkyl Phosphonic Acids of High Enantiomeric Purity" *Tetrahedron Letters*, **1990**, *31*, 6465.
- S. Hanessian, Y. L. Bennani and R. Leger "Structure of a Triphenyltin Adduct: Free Radical Reactions" *Acta Cryst.*, **1990**, *C46*, 701.
- S. Hanessian, Y. L. Bennani and R. Di Fabio "Intramolecular Free-Radical Ring Closures I" *Acta Cryst.*, **1990**, *C46*, 934.
- S. Hanessian, Y. L. Bennani and R. Di Fabio "Intramolecular Free-Radical Ring Closures II" *Acta Cryst.*, **1990**, *C46*, 937.
- S. Hanessian, Y. L. Bennani and R. Di Fabio "Intramolecular Free-Radical Ring Closures III" *Acta Cryst.*, **1990**, *C46*, 939.
- Y. L. Bennani and S. Hanessian "Structure of a Chiral Tricyclic Phosphonamide, $C_{15}H_{26}N_3OPS_2$ " *Acta Cryst.*, **1991**, *C47*, 1230.
- J. Wang, Y. L. Bennani, F. Bélanger-Gariépy and S. Hanessian "Structure of *trans*-1,4-Dihydroxy-*trans*-1,2-Diaminocyclohexane Dichloroplatinum (II) Hydrate" *Acta Cryst.*, **1991**, *C47*, 1067.
- F. B.-Gariépy, Y. L. Bennani, S. Beaudoin and S. Hanessian "Crystal Structure of a β -Hydroxy Bicyclic Phosphonamide: An Asymmetric Olefination Intermediate" *Acta Cryst.*, **1992**, *C48*, 1533.
- K. B. Sharpless, W. Amberg, Y. L. Bennani, G. A. Crispino, J. Hartung, K.-S. Jeong, H.-L. Kwong, K. Morikawa, Z.-M. Wang, D. Xu and X.-L. Zhang "The Osmium-Catalyzed Asymmetric Dihydroxylation of Olefins: A New Ligand Class and a Process Improvement" *Journal of Organic Chemistry*, **1992**, *57*, 2768.
- W. Amberg, Y. L. Bennani, R. K. Chadha, G. A. Crispino, W. L. Davis, J. Hartung, K.-S. Jeong, Y. Ogino, T. Shibata and K. B. Sharpless "Syntheses and Crystal Structures of Cinchona Alkaloids Derivatives as Ligands for the AD of Olefins" *Journal of Organic Chemistry*, **1993**, *58*, 844.
- S. Hanessian, Y. L. Bennani and Y. Hervé "A Novel Asymmetric Synthesis of α & β -amino Aryl Phosphonic Acids" *Synlett*, **1993**, 35.
- H. C. Kolb; Y. L. Bennani and K. B. Sharpless "A Short and Practical Synthesis of (*R*)-(-)-Carnitine and (*R*)-(-)- γ -Amino- α -hydroxybutyric Acid" *Tetrahedron: Asymmetry*, **1993**, *3*, 133.
- Y. L. Bennani and K. B. Sharpless "Asymmetric Dihydroxylation (AD) of *N,N*-Dialkyl and *N,O*-Dimethylhydroxyl α , β - and β , γ -Unsaturated Amides" *Tetrahedron Letters*, **1993**, *34*, 2079.
- Y. L. Bennani and K. B. Sharpless "Easy Access to γ -Hydroxy α , β -Unsaturated Amides via an AD-Elimination Process: Synthesis of (+)-Coriolic Acid" *Tetrahedron Letters*, **1993**, *34*, 2083.
- J. Walsh, Y. L. Bennani and K. B. Sharpless "Asymmetric Dihydroxylation (AD)/Cyclization of DiBoc Allylic and Homoallylic Amines: Selective Differentiation of the Hydroxyl Groups" *Tetrahedron Letters*, **1993**, *34*, 5545.

- S. Hanessian, Y. L. Bennani and Y. Leblanc "Efficient Olefination with α -Alkyl Cyclic Phosphonamides" *Heterocycles*, 1993, 35, 1411.
- S. Hanessian, P. Meffre, M. Girard, S. Beaudoin, J.-Y. Sancéau and Y. L. Bennani "Asymmetric Dihydroxylation of Olefins With A Simple Chiral Ligand" *Journal of Org. Chem.* 1993, 58, 1991.
- M. Arrington, Y. L. Bennani; P. J. Walsh, T. Goebel, S.-H. Zhao and K. B. Sharpless "Modified Cinchona Alkaloid ligands: Improved Selectivities in the OsO_4 Catalyzed AD of Olefins" *Tetrahedron Letters*, 1993, 34, 7375.
- H. C. Kolb, P.G. Andersson, Y. L. Bennani; G. A. Crispino, K.-S. Jeong, H.-L. Kwong and K. B. Sharpless "On the Origin of High Enantioselectivity in the Dihydroxylation of Olefins Using Osmium Tetroxide and Cinchona Alkaloid Catalysts" *J. of the Amer. Chem. Soc.* 1993, 115, 12226.
- Y. L. Bennani, K. VanHessche and K. B. Sharpless "A Short Route to a Mosher's Acid Precursor Via Catalytic Asymmetric Dihydroxylation" *Tetrahedron: Asymmetry*, 1994, 5, 1473.
- S. Hanessian and Y. L. Bennani "Electrophilic Amination of Chiral Alkyl Phosphonamides Asymmetric Synthesis of α -Amino- α -Alkyl Phosphonic Acids" *Synthesis*, 1994, 1272.
- Y. L. Bennani and M. F. Boehm "Syntheses of High Specific Activity Ring-Labeled [^3H]2-9-cis-Retinoic Acid" *Journal of Organic Chemistry*, 1995, 60, 1195.
- Y. L. Bennani "Synthesis of 1-($^{13}\text{CD}_3$)-9-cis-Retinoic Acid" *J. of Lab. Cpd & Radiopharm.*, 1995, 36; 755.
- M. A. Shirley, Y. L. Bennani, M. F. Boehm, A. P. Breau, C. Pathirana and E. H. Ulm "Metabolism of 9-cis-Retinoic Acid in Rat: Reduction, β -Oxidation and Taurine Conjugation" *Drug Met. & Disp.* 1996, 24, 293.
- Y. L. Bennani and S. Hanessian "The Asymmetric Synthesis of α -Methyl and α -Phenyl Phosphonic Acids: Design, Reactivity, Carbanion Geometry and Preparative Aspects of Chiral Alkyl Bicyclic Phosphonamides" *Tetrahedron*, 1996, 52, 13837-13866.
- Y. L. Bennani "An Efficient and Stereoselective Synthesis of 9-cis-Retinoic Acid": *Journal of Organic Chemistry*, 1996, 61, 3542.
- Y. L. Bennani, C.H. Hwang, S. Canan-Koch, K. Marron, L. Dardashti, B.-A. Badea and A. M. Nadzan "Synthesis of Geometrically Restricted α,β -Unsaturated Esters" *Tetrahedron Letters*, 1996, 17, 8109.
- Y. L. Bennani and S. Hanessian "Trans-1,2-Diaminocyclohexane Derivatives as Efficient Chiral Auxiliaries in Asymmetric Synthesis and Molecular Recognition" *Chemical Reviews*, 1997, 97, 3161-3196.
- Y. L. Bennani, M. F. Boehm, D. Mais, K. Flaten and A. Nadzan "Retinoic Acid Receptors: Synthesis and Characterization of A Highly Selective Radiolabeled Ligand" *Journal of Organic Chemistry*, 1998, 63, 543.
- Y. L. Bennani, G.-D. Zhu and J. C. Freeman "Scandium-Mediated Opening of Aziridine Carboxylates: A Facile Synthesis of Aryl-Substituted Tryptophans" *Synlett* 1998, 754.
- R. Faghih, H. N. Nellans, P. A. Lartey, A. Petersen, K. Marsh, Y. L. Bennani and J. J. Plattner; "Preparation of 9-deoxo-4"-deoxy-6,9-epoxyerythromycin lactams "Motilactides": Potent and Orally active Prokinetic Agents" *Bioorganic & Medicinal Chemistry Letters* 1998, 8, 805.
- R. Faghih, P. A. Lartey, Hugh N. Nellans, Cynthia Burnell-Curti, L. Seif, P. Thomas, A. Petersen, K. H. Kim, A. Borre, T. Pagano, L. L. Klein, M. Heindel, Y. L. Bennani and J. J. Plattner "Synthesis of 9-Deoxo-4"-deoxy-6,9-epoxyerythromycin Derivatives: Novel and Acid Stable Motilides" *J. Med. Chem.* 1998, 41, 3408.
- R. Faghih, C. Burnell-Curti, P. Lartey, A. Petersen, L. L. Klein, Y. L. Bennani, H. N. Nellans, "Synthesis of 8(R), 9(R)-9-Deoxo-4"-deoxy-6,9-epoxy-erythromycin: Potent Motilides" *European J. Medicinal Chemistry* 1999, 34, 264.
- R. C. Goldman and Y. L. Bennani "Rapamycin, FK506 and Cyclosporine as Antifungal agents" *Recent Res. Develop. Antimicrobial Agents-Chemother.* 1999, 3, 383-405.
- Daniel A. Dickman, Hong Ding, Qun Li, Angela M. Nilius, Darlene J. Balli, Stephen J. Ballaron, James M. Trevillyan, Morey L. Smith, Ki Kim, Aparna Sarthy, Robert C. Goldman, Jacob J. Plattner and Youssef L.

Bennani "Antifungal Rapamycin Analogues With Reduced Immunosuppressive Activity" *Bioorganic & Medicinal Chemistry Letters* 2000, 1405.

- Cruz MC, Goldstein AL, Blankenship J, Del Poeta M, Perfect JR, McCusker JH, Bennani YL, Cardenas ME, Heitman J. "Rapamycin and Less Immunosuppressive Analogs Are Toxic to *Candida albicans* and *Cryptococcus neoformans* via FKBP12-Dependent Inhibition of TOR." *Antimicrob. Agents Chemother.* 2001 45(11): 3162-70.
- Bennani, Y. L. et al. "Discovery, SAR and Biochemical Characterization of A192411: A novel Fungicidal lipopeptide-I" *Bioorganic & Medicinal Chemistry Letters* (2001) "Submitted".
- Bennani, Y. L. et al. "Synthesis of A192411: A novel Fungicidal lipopeptide-II" *Bioorganic & Medicinal Chemistry Letters* (2001) "Submitted".
- Bennani, Y. L. et al. "In vitro & In vivo Characterization of A192411: A novel Fungicidal lipopeptide-III" *Bioorganic & Medicinal Chemistry Letters* (2001) "Submitted".
- Fox GB, Pan JB, Esbenshade TA, Bennani YL, Black LA, Faghah R, Hancock AA, Decker MW. "Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup" *Behav. Brain Res.* (2002); 131(1-2):151-61.

In preparation

- B.-A. Badea, Y. L. Bennani, S. Canan-Koch, C.-K. Hwang, A. Nadzan and S. K. White "Tricyclic Retinoid Pan Agonists: Analogues of 9-cis-Retinoic Acid with Potent Antiproliferative Activity" *Bioorg. & Med. Chemistry Letters* (2002) "In Preparation"
- B.-A. Badea, Y. L. Bennani, S. Canan-Koch, C.-K. Hwang, A. Nadzan and S. K. White "Retinoic Acid Receptor Selective Ligands: Tricyclic Analogues of all-trans-Retinoic Acid:" *Bioorganic & Medicinal Chemistry Letters* (2002) "In Preparation"
- Y. L. Bennani, K. Marron, S. Canan-Koch, C. H. Hwang, L. J. Farmer, A. M. Nadzan, Dale Mais and Karen Flaten "Novel Aza-Retinoids as RXR selective Agonists" *Bioorganic & Medicinal Chemistry Letters* (2002) "In Preparation"-Awaiting Patent clearance.
- Y. L. Bennani, M. F. Bohem, M. Shirley, E. Ulm and A. Nadzan "Retinoic Acid Receptors: Metabolism of A Highly Selective Retinoic Acid Receptor Agonist" *Drug Metabolism and Disposition* (2002) "In Preparation".
- Sarthy, A.V.; McGonigal, T.; Capobianco, J. O.; Coen, M.; Zakula D.; Bennani, Y. L.; Goldman, R. C. "Kinetic Analysis of Multiple Forms of Translation Elongation Factor-3 from *Candida Albicans*", *European J. of Biochemistry* (2002) "In Preparation".

Presentations

Bush, E.N., R. Shapiro, M. Nuss, V. Knourek-Segel, D. Wilcox, B. Droz, R.; Faghih, Y. Bennani, T. Esbenshade, P.B. Jacobson, and A.A. Hancock, The histamine H3 receptor antagonist A-331440 decreases body weight in male C57BL/6J Mice with High Fat Diet-Induced Obesity, Abstracts American Diabetes Association, June 14-18, 2002.

Faghih, R., K. Phelan, T. Esbenshade, T. Miller, C-H. Kang, K. Krueger, B. Yao, G.B. Fox, Y.L. Bennani and A.A. Hancock, Structure activity relationships of piperazine-amides: Novel H3-receptor antagonists: Binding preference for D-amino-acid motifs, Abstracts, European Histamine Research Society, May 22-26, 2002.

Fox, G.B., J.B. Pan, R. Faghih, T.A. Esbenshade, R.S. Bitner, L. Black, Y. Bennani, M.W. Decker and A.A. Hancock, Identification of novel centrally acting H3 receptor (H3R) antagonists with cognition-enhancing properties in rats, Abstracts, European Histamine Research Society, May 22-26, 2002.

Yao, B.B., D. Witte, T.L. Carr, S. Cassar, K.M. Krueger, T.M. Miller, C.H. Kang, C.W. Hutchins, R. Faghih, T.A. Esbenshade, Y. Bennani and A.A. Hancock, In vitro pharmacology of two novel piperazine amide H3 receptor (H3R) antagonists, Abstracts, European Histamine Research Society, May 22-26, 2002.

Hancock, A., G. Fox, E. Bush, R. Shapiro, M. Nuss, V. Knourek-Segel, D. Wilcox, B. Droz, P. Jacobson, Y. Bennani, T. Esbenshade and R. Faghih, Blockade of CNS-H3-Receptors by and Anti-obesity Effects of the Histamine H3 Receptor Antagonist, A-331440, Abstracts, IUPHAR, San Francisco, CA, July 7-12, 2002.

Krueger, K.M., C.H. Kang, T. Miller, D. Witte, R. Faghih, Y. Bennani, T.A. Esbenshade, and Hancock, A., Pharmacological properties of the novel histamine H3 receptor antagonist, A-331440, Abstracts, IUPHAR, San Francisco, CA, July 7-12, 2002.

Black, L.A., R. Faghih, J. Liu, W. Dwight, K. Phelan, R. Gentles, T. Esbenshade, L. Ireland, T. Miller, C-H. Kang, A.S. Parihar, K. Krueger, G.B. Fox, Y.L. Bennani and A.A. Hancock, Acyl-D-alanine amides: selective histamine H3 receptor antagonists, Abstracts of papers of the American Chemical Society Meeting, MEDI, 2002.

Komater, V., G. Fox, P. Curzon, T. Esbenshade, Y. Bennani, A.A. Hancock and M. Decker, H3 receptor blockade by thioperamide enhances cognition without inducing psychomotor sensitization, unlike methylphenidate, amphetamine or cocaine, Abstracts, Society for Neuroscience, 2002.

Yao, B.B., D.G. Witte, T.L. Carr, S. Cassar, K.M. Krueger, T.R. Miller, C.H. Kang, C. W. Hutchins, R. Faghih, Y.L. Bennani, T.A. Esbenshade and A.A. Hancock, Two novel piperazine amide H3 receptor (H3R) antagonists and their in vitro pharmacology, Abstracts, Society for Neuroscience, 2002.

A.A. Hancock, K.M. Krueger, C.H. Kang, T. Miller, D. Witte, S. A. Buckner, I. Milicic, G.B. Fox, E.N. Bush, R. Shapiro, M. Nuss, V. Knourek-Segel, D. Wilcox, B. Droz, J.B. Pan, P.B. Jacobson, Y. Bennani, T.A. Esbenshade and R. Faghih, Pharmacology of a novel histamine H3 receptor antagonist with favorable effects in diet-induced obesity in mice, Abstracts, Society for Neuroscience, 2002.

Fox, G.B., J.B. Pan, A. Lewis, R. Faghih, T.A. Esbenshade, L. Black, Y. Bennani, M.W. Decker and A.A. Hancock, Novel, centrally acting, non-imidazole H3 receptor (H3R) antagonists enhance cognition in rats, Abstracts, Society for Neuroscience, 2002.

Patents & Applications

- Y. L. Bennani "Synthesis of Ring-Labeled 9-cis-Retinoic Acid" 1994 "PCT.US95/16842".
- Y. L. Bennani "A Novel Synthesis of 9-cis-Retinoic Acid" 1994 "PCT.US95/06580".
- Y. L. Bennani and M. F. Boehm "Methods for the Synthesis of Tritium Labeled Retinoids; Their Novel Intermediates and Use in Discovering Retinoid X Receptor Ligands"-US5514821, 1996.
- C. H. Hwang, S. White, Y. L. Bennani, S. Canan-Koch, J. J. Hebert, B. A. Badea, A. Nadzan, L. Farmer "Novel Tricyclic Retinoids for Cancer Treatment" 1996 "WO9620914-A1".
- M. F. Boehm, L. Zhang, Y. L. Bennani and Alex M. Nadzan "Novel Trienoic Compounds and Methods", 1996 "WO9620913".
- Y. L. Bennani, R. Faghah and L. Seif "New Process for the Preparation of 8(S), 9(R)-6,9-Epoxyerythromycin" "Pat.: D19885-1998".
- Y. L. Bennani, K. Marron, S. Canan-Koch, C. H. Hwang "Aza-Retinoids as RXR selective Agonists" (1997) "Patent Submitted".
- Y. L. Bennani et al. "Preparation of Cyclic Hexapeptides As Antifungal & Antipneumocystic Agents" US22844.
- C. H. Hwang, S. White, Y. L. Bennani, S. Canan-Koch, J. J. Hebert, B.-A. Badea, A. Nadzan, L. Farmer "Preparation of Tricyclic Retinoids as Retinoid Receptor Agonists" 1999; US 5770383/US5770378.
- C. H. Hwang, S. White, Y. L. Bennani, S. Canan-Koch, J. J. Hebert, B.-A. Badea, A. Nadzan, L. Farmer "Methods for the production and use of tricyclic retinoids" 1999; 75 pps-EP933350.
- Y. L. Bennani et al. "Novel Cyclic Peptides As Antifungal Agents" Pat. Filed 12-1999.
- Bennani, Youssef L.; Black, Lawrence A.; Dwight, Wesley J.; Faghah, Ramin; Gentles, Robert G.; Liu, Huqing; Phelan, Kathleen M.; Vasudevan, Anil; Zhang, Henry Q. Cyclic and bicyclic diamino histamine-3 receptor antagonists. PCT Int. Appl. (2001) WO 0166534, A2-20010913, AN 2001:676758.
- Bennani, Y. L. and Ramin Faghah; "Aminoalkoxybiphenyl carboxamides as Histamine-3 receptor ligands and their therapeutic applications"; U.S. Patent Number: 6,316,475, 2001
- Bennani, Y. L.; R. Faghah, W. Dwight "1,3-Disubstituted and 1,3,3-Trisubstituted Pyrrolidines As Histamine 3-Receptor Ligands and Their Therapeutic Applications" Patent application filed 9/2000: PCT 6709.US-01.
- Bennani, Youssef L.; Faghah, Ramin; Dwight, Wesley J.; Vasudevan, Anil; Conner, Scott E. 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications. PCT Int. Appl. (2002), 146 pp. WO 0206223.
- Bennani, Youssef L.; Faghah, Ramin; Dwight, Wesley J.; Vasudevan, Anil; Conner, Scott E. "1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications (USA). U.S. Pat. Appl. Publ. (2002), CODEN: USXXCO US 20020035103-A1 20020321 Patent - Application: US 2001-902925-20010711. Priority: US 2000-218084 20000713. AN 2002:221215
- Cyclic and bicyclic diamino histamine-3 receptor antagonists. Bennani, Youssef L.; Black, Lawrence A.; Dwight, Wesley J.; Faghah, Ramin; Gentles, Robert G.; Liu, Huqing; Phelan, Kathleen M.; Vasudevan, Anil; Zhang, Henry Q. (USA). U.S. Pat. Appl. Publ. (2001), US 20010049367 A1 20011206

- Y. L. Bennani et al. "Pyrrolidinopyrrolidines As H3-Receptor Antagonists" Abbott-D-20416-(2000) "Filed"
- Y. L. Bennani et al. "Bicyclic-Fused Amines as H3-Receptor-Antagonists"-Abbott-D-20412-(2000) "Filed"
- Y. L. Bennani et al. "Histamine 3-Receptor Antagonists Especially for Attention Deficit, Cognition Enhancement"-Abbott-D20480-(2000) "Submitted".
- Y. L. Bennani et al. "Cyclopropylphenyl Amines As H3-Receptor Antagonists" Abbott-(2000) "Submitted"
- Y. L. Bennani et al. "Symmetrical Amines as H3-Receptor Ligands" Abbott-D-20325-(2000) "Submitted"
- Y. L. Bennani et al. "Tricyclic Histamine-3-Receptor Ligands" Abbott-D-20403-(2000) "Submitted".
- Y. L. Bennani "2-Alkyl-hexynoic Amides and Their Therapeutic Uses" Abbott-D-20403-(2000) "Filed".
- Hancock A.; Bush, E.; Cowart, M.; Jacobson, P.B.; Opgenorth, T.; Bennani, Y. "Histamine-3 receptor Antagonists for the treatment of Diabetes" case filed, (2002), 6872.US.01.


Summary

Over the years, Dr. Bennani has contributed to a wide variety of research programs, therapeutic areas and types of biological/chemical drug-class targets with emphasis on drug candidates. He contributed and is associated with:

- one clinically marketed drug (Panretin) (Ligand Pharmaceuticals)
- one clinical agent presently ongoing human clinical trials (ABT-239- Abbott laboratories)
- two late-stage pre-clinical compounds (ABT-086, and other agent)

Dr. Bennani has published several scientific papers and holds a number of patents (*see addendum*). He has gained experience in managing several research groups and chemistry programs and was involved in establishing and managing several industrial and academic research collaborations throughout his career. In addition to his academic scientific training, he holds a MBA with emphasis on International business, Strategy, and Leadership; and has attended several courses related to personnel and science management. His management experience includes presentations at Scientific Advisory Board meetings (Abbott Laboratories) and several internal strategic Therapeutic Area and Project research reviews as well as international venues. He has managed research operations for a variety of group sizes and diverse scientific, personnel and strategic challenges. His scientific and drug discovery experience spans the following areas:

- Organic & medicinal chemistry/Drug discovery: structure based drug design; natural product synthesis; organic synthesis; peptide chemistry; combinatorial and parallel synthesis; radiochemistry; organometallic asymmetric catalysis; small molecule crystallography.
- Oncology, Metabolic, Infectious and Neurological diseases research (direct involvement):
- Intracellular/nuclear receptor modulation (RARs/RXRs/PPARs etc.).
- Cell surface growth factor receptors/cytokine mimicking (EPO/G-CSF/TPO).
- Gastrointestinal motility (Erythromycin based motilides, GPCR-motilin receptors).
- Immunoregulation (Glycoside/Glucans-based research: CR3, PLA2, PGE2, FKBP-TOR/FRAP).
- Antifungal therapy (Glucan Synthase inhibition & Yeast translation factors modulation: EF3 etc.).
- Neurological diseases (GPCR-modulation: ADHD, epilepsy, bipolar disorders, obesity and pain).
- Cross-functional experience in microbiology, molecular biology, *in-vitro* & *in-vivo*-pharmacology, PK-PD, ADME-Toxicity and Cardiovascular safety.



Patentability of Reach-Through Claims


Brian R. Stanton

Practice Specialist

Technology Center 1600


(703) 308-2801

Brian.stanton@uspto.gov




Exemplary Reach Through Situations

- 1. Small molecule per se claim, where the molecule is defined as binding to target but not yet identified (e.g. "A receptor [X] agonist").
- 2. Method of screening claim: how effectively does this claim protect a small molecule identified in the screen?
- 3. "Functional use" claim: claim is to a method of treating a disease by a compound defined not by its structure but rather by its ability to bind to a target (e.g. "A method of treating disease [Y] by administering a compound which is a receptor [X] agonist."



Major Patentability Issues


- Utility (35 U.S.C. 101)
 - See Utility Examination Guidelines
 - 66 *Fed. Reg.* 1092 (Jan. 5, 2001)
 - Written Description (35 U.S.C. 112, 1st para.)
 - See Written Description Examination Guidelines
 - 66 *Fed. Reg.* 1099 (Jan. 5, 2001)
 - Enablement (35 U.S.C. 112, 1st para.)
 - Novelty (35 U.S.C. 102)
 - Nonobviousness (35 U.S.C. 103)



Receptor Claims

► Major Patentability Issue - Utility


- If applicant shows at least one specific, substantial, and credible utility for the receptor, and other statutory requirements are met, applicant is entitled to a patent on the receptor *per se*.



Receptor Claims


► Scope of Protection

- An inventor with a patent to a specific receptor has the right to exclude others from using said receptor in a screening assay for identifying agonists or antagonists that can be used to treat a disease.
- 35 U.S.C. 271(a): "Except as otherwise provided in this title, whoever without authority makes, uses, offers to sell, or sells any patented invention, within the United States, or imports into the United States any patented invention during the term of the patent therefor, infringes the patent."
- Selling drugs that could have been developed through use of the receptor itself is not necessarily infringement



Receptor Agonist Claims

- Types of claims at issue:
 - “A receptor [X] agonist.”
 - “A method of treating disease [Y] by administering a compound which is a receptor [X] agonist.”




Receptor Agonist Claims

► Major Patentability Issue - Written Description

- Generic claim to “A receptor [X] agonist.” unlikely to comply with written description requirement:
 - No description of structure of representative number of claimed compounds
 - No description of chemical or physical characteristics of representative number of claimed compounds or of function of representative number of claimed compounds (other than binding to identified receptor)
- Analogous to *Regents of the Univ. of Cal. v. Eli Lilly & Co.*, 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997)(description of how to obtain compounds not sufficient without description of what the compounds are)


► See also *Fiers v. Revel*, 984 F.2d 1164, 25 USPQ2d 1601 (Fed. Cir. 1993);
In re Ruschig, 379 F.2d 990, 154 USPQ 118 (CCPA 1967)



Receptor Agonist Claims


► Major Patentability Issue - Enablement

- Specification must teach how to make and use the full scope of the claimed invention without undue experimentation.
- Apply factors set forth in *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)
 - Breadth of the claims
 - Nature of the invention
 - State of the prior art
 - Relative skill of those in the art
 - Level of predictability in the art
 - Amount of direction provided by the inventor(s)
 - Existence of any working examples
 - Quantity of experimentation needed



Receptor Agonist Claims


- Major Patentability Issue - Enablement
 - Generic claim to “A receptor [X] agonist.” unlikely to comply with enablement requirement:
 - The specification does not usually teach how to make and use the full scope of agonists or antagonists within that genus without undue experimentation.
 - Specification usually teaches how to identify compounds, rather than how to make them; specification does not usually teach how to use the full scope of the compounds within the genus without undue experimentation.



Receptor Agonist Claims

- Major Patentability Issue - Enablement


- If a claim to “A receptor [X] agonist” meets the utility, enablement and written description requirements, a claim to “A method of treating disease [Y] by administering a compound which is a receptor [X] agonist” must still be supported by an enabling disclosure.
- Will compound operate as intended without undue experimentation?



Combinatorial libraries

► Major Patentability Issue - Utility

- Must have a specific, substantial and credible utility for the collection of elements making up the library (e.g., as an extrinsic research tool)
- Individual members of the library may not have specific, substantial and credible utilities.
- *The utility that serves to meet the requirements of 35 U.S.C. §101 relates to the use of the library rather than to the individual members thereof (in the absence of a specific disclosure of a use for an individual member).*




Combinatorial Libraries

► Major Patentability Issue - Written Description

- A disclosure of a collection of molecules does not necessarily provide support for a claim drawn to any particular individual member of the collection.
- Possession of a genus does not imply possession of any particular member of genus.


- See *Fujikawa v. Wattanasin*, 93 F.3d 1559, 39 USPQ2d 1895 (Fed. Cir. 1996) and *In re Ruschig*, 379 F.2d 990, 154 USPQ 118 (CCPA 1967).
- See also *In re Bell*, 991 F.2d 781, 26 USPQ2d 1529 (Fed. Cir. 1993) and *In re Baird*, 16 F.3d 380, 29 USPQ2d 1550 (Fed. Cir. 1994).



Combinatorial Library

► Scope of protection


- Right to exclude others from making, using, selling, offering for sale, or importing the library
 - Using a patented library in a screening method for compounds of interest may constitute infringement
- Does a patented claim to a collection of components confer exclusionary rights to the individual members of the collection?
 - It is the collection of molecules, not the individual components, that is protected by a claim to a combinatorial library.



Methods of Screening (Combinatorial Libraries; Receptors)

► Major Patentability Issue - Utility


- Requirement met if screening method identifies a ligand which acts upon a receptor so as to effect a specific, substantial, and credible use
- Requirement met if the asserted utility for screening a combinatorial library is specific, substantial, and credible.



Methods of Screening (Combinatorial Libraries; Receptors)

➤ Scope of Protection

- Claim prevents others from making, using, selling, or offering for sale the claimed screening method.
- A product identified by a screening method is **not** a product made by a patented process.
- 35 U.S.C. 271(g) includes use, sale, or importation of a product made by a patented process as an act of infringement.



Products Identified by Methods of Screening (Combinatorial Libraries; Receptors)

- Major Patentability Issues - Written Description and Enablement
 - Same analysis as for receptor agonist claims (discussed earlier)

THANK YOU

